Close Menu

Webinar/Video Library

GenomeWebinar

Laboratory Head
IMD Labor Frankfurt

Biologist
Seq-IT

Vice President, Scientific Affairs
Agena Bioscience

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.  Understanding the impact of these variants on molecular testing methods and how labs can address this added complexity is important to managing the diagnostic response to the ongoing pandemic.

In this webinar Dr. Martin Stürmer of IMD Labor Frankfurt will discuss the effects of emerging SARS-CoV-2 variants on diagnostic methods and the clinical utility of detecting and discriminating them. Thomas Alef of Seq-IT will then present how his clinical lab was able to react to the emergence of new, often more contagious, variants of the virus by rapidly designing a highly multiplexed SARS-CoV-2 variant panel using the low-cost, high-throughput MassArray System from Agena Bioscience.

Sponsored by
GenomeWebinar

Medical Director, Precision Medicine;
Geriatric Oncology Consortium

Chief, Precision Health and Genomics,
Intermountain Healthcare

Research Scientist, Personalized Medicine Specialist,
DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center

Co-Director, Oncology Precision Medicine Program,
Aurora Health Care

Lead Variant Scientist,
Intermountain Healthcare

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

US Food and Drug Administration approvals for targeted anticancer therapy are most often for specific types of cancer that possess specific driver mutations. However, the broad application of comprehensive genomic profiling has identified the presence of potential “druggable” driver mutations in malignancies for which FDA approval is not yet obtained.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series 

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.


Sponsored by
GenomeWebinar

Director, Strategy and Business Development,
Qorvo Biotechnologies

VP Business Development,
Schott Minifab

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

This has been the case with the development and quick manufacturing scaleup of Qorvo's COVID-19 test. Primary among these challenges has been acquiring and coordinating broad multidisciplinary expertise among Qorvo’s team of people and partners; successfully cultivating the capabilities and culture to be flexible and innovative in face of extreme uncertainty; and, lastly, developing access to broad manufacturing scalability to accommodate the flexibility needed from product development to high-volume manufacturing.

This webinar will present a case study outlining Qorvo's path in developing and commercializing its COVID-19 test. In so doing, participants can expect to learn:

  • Key challenges of diagnostic test development, both anticipated and unanticipated
  • Relevant factors during development that are important to eventual successful commercialization
  • Perspective on the need for development and manufacturing partners and what capabilities they should possess.
Sponsored by
February 23, 2021
Sponsored by
Thermo Fisher Scientific

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

GenomeWebinar

R&D Scientist IV,
ARUP Laboratories

Director, Clinical Product Development, Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. Labs face new challenges such as having to process large volumes of samples with a quick turnaround time, the constant risk of falling into backlog, and the possibility of loss of reimbursement (for certain samples). But what happens after the surge, when infection rates decline but testing will still be a necessary component of managing the virus? 

During this presentation, Weston Hymas of ARUP Laboratories will discuss the clinical validation of a SARS-CoV-2 sample pooling protocol that can be used to exponentially increase testing efficiency, enabling a higher volume of sample processing in lower prevalence rate populations. This method can be implemented by clinical labs for routine processing of samples from populations with low infection rates. 

Sponsored by
Partner Webinar

Clinical Molecular Geneticist
University Health Network

Development Technologist II and Assistant Professor in the Genomics Laboratory, Mayo Clinic

VP of Clinical Product Management and Marketing, Qiagen

Technical Director,  Pangaea Oncology; Quiron Dexeus University Hospital

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Recently, GenomeWeb and Qiagen partnered on a survey that allowed participants to assess their oncology variant interpretation workflows. This webinar will present the results of the survey and offer an interactive environment for clinical labs to assess their own variant interpretation capabilities.

The discussion will cover a range of capabilities related to variant interpretation workflows, including:

  • Resources and skills
  • Workflow optimization
  • Variant interpretation content knowledge.

Panelists will share their experiences in implementing and optimizing their own variant interpretation pipelines. The session will wrap up with a live Q&A in which attendees can ask questions of our expert panelists.

Sponsored by
GenomeWebinar

Associate Professor,
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. However, it has been unclear how tumor-specific inflammatory processes relate to inflammation in non-malignant tissues.

This webinar will discuss a single-cell study that compared the immune landscape of human head and neck squamous cell carcinoma (HNSCC) in the oral and oropharyngeal cavity to inflamed oral mucosal tissue samples, in an effort to identify tumor-unique immune alterations.

Dr. Martin Prlic of the Fred Hutchinson Cancer Research Center will share details of the project, which found a considerable phenotypic congruence of immune cells in inflamed versus tumor tissues, including the presence of T cells with an exhausted phenotype as well as recently described mature dendritic cells enriched in immunoregulatory molecules (mregDCs).

Computational and machine learning analyses revealed previously unidentified tumor-unique immune subsets and signaling axes, while experimental validation confirmed a tumor-unique subset of regulatory T cells (Tregs).

Attendees of this webinar will learn:

  • How cutting-edge single-cell techniques are used to study the microenvironment in human tissue samples
  • Insights into the immune alterations in the human tumor microenvironment
  • A blueprint for a novel discovery approach of immunotherapeutic targets in the human tumor microenvironment
Sponsored by
GenomeWebinar

Research Scientist,
Leroy Hood Lab, Institute for Systems Biology

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.

In this webinar, Dr. Yapeng Su of the Institute for Systems Biology will present an integrated analysis of the clinical measurements, immune cells, and plasma multiomics of 139 COVID-19 patients representing all levels of disease severity, from serial blood draws collected during the first week of infection following diagnosis.

As recently published in Cell, Dr. Su’s team identified a major shift between mild and moderate disease, at which point elevated inflammatory signaling is accompanied by the loss of specific classes of metabolites and metabolic processes. Within this stressed plasma environment at moderate disease, multiple unusual immune cell phenotypes emerge and amplify with increasing disease severity.

Dr. Su and colleagues condensed more than 120,000 immune features into a single axis to capture how different immune cell classes coordinate in response to SARS-CoV-2. This immune-response axis independently aligns with the major plasma composition changes, with clinical metrics of blood clotting, and with the sharp transition between mild and moderate disease.

This study suggests that moderate disease may provide the most effective setting for therapeutic intervention.

Sponsored by
February 16, 2021
Sponsored by
Thermo Fisher Scientific

Differentiate DNA from RNA using NanoDrop Spectrophotometers

Partner Webinar

The similarity of absorbance spectra between DNA and RNA makes typical UV-Vis analysis less effective at distinguishing the two nucleic acids. It results in a greater risk of spending time and resources on downstream measurements only to find that the DNA sample was contaminated with RNA or vice versa. The researcher shoulders the responsibility of ensuring sample purity at the start for success down the line. 

This 13-minute video reviews how absorbance is used to analyze nucleic acid samples. It also shows how modern UV-Vis spectrophotometer software using chemometric modeling can detect DNA/RNA contamination in samples and provide corrected concentrations.

Sponsored by
Partner Webinar

Senior Research Scientist in the Regev Lab,
Broad Institute of MIT and Harvard

Application Scientist, Advanced Cell Diagnostics 

This on-demand webinar discusses a project at the Broad Institute to use spatial profiling to understand the disease progression of COVID-19. 

Sami Farhi of the Broad Institute shares details of the project, which performed transcriptomic and proteomic spatial analysis on lung parenchyma from rapid autopsies of patients succumbing to the disease. 

The team used NanoString GeoMx to perform whole-transcriptome, cancer transcriptome, and protein studies on 17 donor samples. More than 12 regions of interest were selected for each donor, guided by RNAScope against the SARS-CoV-2 S gene to identify regions of high and low viral load. 

Farhi and colleagues performed differential analyses of epithelial and non-epithelial compartments across different viral load, anatomical compartment, and inflammation status. Results matched conclusions from single-cell and bulk RNA sequencing data on the same samples. 

Dr. Farhi discusses how the study highlights the utility of RNAScope in guiding other spatial analysis methods as well as how the data set captures the intra- and inter-sample expression heterogeneity associated with COVID-19, highlighting both early response mechanisms to SARS-CoV-2 and subsequent late-stage responses to viral damage.

Key Learning Points:

  • Spatial variation of gene expression programs in COVID-19 tissues
  • Guiding Nanostring GeoMx experimental design with RNAScope measurements
Sponsored by
February 11, 2021
Sponsored by
Foundation Medicine

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

GenomeWebinar

Medical Director, Precision Medicine;
Geriatric Oncology Consortium

Chief, Precision Health and Genomics, Intermountain Healthcare

Research Scientist, Personalized Medicine Specialist
DeBartolo Family Personalized Medicine Institute, H. Lee, Moffitt Cancer Center

Co-Director, Oncology Precision Medicine Program, Aurora Health Care

Lead Variant Scientist, Intermountain Healthcare

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Initial interest in homologous recombination genes was focused on pathologic mutations associated with risk of inherited breast, prostate, pancreatic, and/or gynecological malignancies. HRD has recently emerged as a biomarker to predict sensitivity to PARP inhibitors, and the identification of these alterations has become important, accordingly.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series 

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.



Sponsored by
February 02, 2021
Sponsored by
Olink

Accelerating Proteomics with Proximity Extension Assay

Partner Webinar

The short video provides an overview of the Proximity Extension Assay technology that lies behind the Olink Explore 1536 proteomics platform, which includes next-generation sequencing readout for human protein biomarker research.

The animation explains how Olink's innovative dual recognition, DNA-coupled methodology provides exceptional readout specificity, enabling high multiplex, rapid throughput biomarker analysis without compromising data quality.

Sponsored by
GenomeWebinar

Director of the Molecular Diagnostics Laboratory, Director of the Molecular Genetic Pathology Fellowship, Clinical Associate Professor of Pathology, University of Michigan

This webinar discusses how the University of Michigan has implemented a new next-generation sequencing (NGS) capture-based solution to assess myeloid malignancies while minimizing required laboratory resources. 

The evolution of molecular oncology presents enormous challenges for laboratories, including:

  • Selecting clinically relevant genomic regions using the most up-to-date medical evidence
  • Designing and optimizing an advanced NGS solution
  • Implementing bioinformatics technology for accurate variant calling
  • Utilizing expertise for variant annotation and interpretation

In this webinar, Dr. Noah Brown of the University of Michigan will discuss how his team worked with Sophia Genetics to develop an NGS solution to keep pace with the ever-evolving recommendations and clinical guidelines for myeloid malignancies. 

In particular, he will describe:

  • The optimization of laboratory resources and rationale for external collaboration
  • Myeloid panel design considerations
  • The process of implementing this new NGS capture-based solution
  • Analytical performance 
  • Experience with this platform in routine testing

Product Disclaimer: Sophia Genetics products are for Research Use Only and not for use in diagnostic procedures. The information included has been prepared for and is intended for viewing by a global audience. Information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please consult local sales representativesAny views expressed during this webinar by the presenter are those of the presenter only and do not represent Sophia Genetics' own views.

Sponsored by
January 26, 2021
Sponsored by
Paragon Genomics

SARS-CoV-2 Sequencing and High-Throughput Detection

Partner Webinar

In this on-demand webinar, speakers from Paragon Genomics and Children's Hospital Los Angeles discuss the newest applications and methods for identifying and investigating the SARS-CoV-2 genome.

Technical Specialist and Operations Manager Lily Liu introduces the Paragon team's latest research and product while Dr. Xiaowu Gai and Dr. Jennifer Dien Bard of Children's Hospital Los Angeles discuss how they have integrated the Paragon Genomics SARS-CoV-2 kit into their research workflow.

Sponsored by
GenomeWebinar

Director of Aquaculture Innovation,
Atlantic Aqua Farms

Lead Scientist, Variety Development and Bioinformatics,
Hopsteiner

Genomics Coordinator, The Center for Aquaculture Technologies (CAT)

Global Strategic Marketing Manager,
LGC, Biosearch Technologies

Reduced representation next-generation sequencing (NGS) methods are driving understanding of both physical and structural variation in all species. But these services are not created equal. The diversity of species means that not all breeding programs can rely on well-defined reference genomes. For many species, customized enzymes and expertise help uncover more variations and make more informative decisions on breeding selections.

For example, genotyping by sequencing (GBS) is a useful approach for species where there is little or no previous genetic information available. The approach provides a means for SNP discovery for lesser interrogated species and unique populations where whole-genome sequencing would not be financially feasible due to complexities and larger genome sizes.

In this panel discussion, three experts will talk through applications of targeted genotyping by sequencing, specifically focusing on how customized enzymes coupled with expertise from LGC, Biosearch Technologies, improved their breeding programs.

Sponsored by
Partner Webinar

In this technical presentation, we will discuss the use of polymeric microspheres in diagnostic assays. We will provide you with a survey of the materials used in this field, examples of readers available for this growing market, case studies, and a first preview of novel products to be released in 2020.  Material considerations to be discussed include key attributes needed to select the best spheres for qualitative and quantitative assays (such as size, functional group, and color).  We will also share best practices to troubleshoot protein binding in qualitative assay development using our raw materials. This information will be of interest to individuals involved in developing and validating qualitative and quantitative assays.

Sponsored by

Pages

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.

Interested in Posting your Webinar or White Paper on GenomeWeb?

Contact us